Quantcast

PRA Expands Operations in the Balkan Region

July 12, 2011

RALEIGH, N.C., July 12, 2011 /PRNewswire/ — PRA, a leading Clinical Research Organization, announces the recent creation of a legal entity in Bulgaria to support continued growth and expand operations in the Balkan area. Located in Sofia, the new entity will enhance PRA’s local presence, provide a solid base for growth, and strengthen PRA’s ability to provide professional quality clinical services in Bulgaria and neighboring countries.

PRA began operating in Romania and Greece in 2006, and demand for services in the Balkan region has steadily increased and expanded to Turkey and Bulgaria. PRA’s staff has grown accordingly and the number of feasibilities and awarded projects nearly tripled in the past year alone.

“In addition to our presence in the Central and Eastern European region, PRA’s new entity in Bulgaria is a part of our strategic growth and development that clearly demonstrates our commitment to expansion,” said Dr. Ludger Langer, PRA’s Vice President of Clinical Operations in Europe, Asia-Pacific and Africa.

With over 40 offices worldwide, PRA continues to grow and expand into new regions for clinical research. The legal entity in Bulgaria further demonstrates our commitment to meeting the expanding needs of our clients in an ever-changing clinical trials environment and provides our local teams with a local corporate basis for operations.

About PRA

PRA is transforming clinical trials through our people, innovation and transparency. PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge. Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. But at PRA, we are looking to the future, not the past. Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email endpoints@praintl.com or call our Global Headquarters.

SOURCE PRA


Source: newswire



comments powered by Disqus